olaparib (lynparza) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Olaparib is an oral inhibitor of poly (ADP-ribose) polymerase enzymes, including PARP1, PARP2, and PARP3 which are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has shown activity in ovarian and breast tumors with known BRCA mutations and was the first FDA approved drug in this class. Lynparza (olaparib) is indicated for treatment of gBRCA-mutated advanced ovarian cancer. Its use together with other chemotherapy medicines can lead to increased effects on the blood resulting in reduction in the numbers of white blood cells and platelets, and anaemia.   NCATS

  • SMILES: FC1=CC=C(CC2=NNC(=O)C3=C2C=CC=C3)C=C1C(=O)N4CCN(CC4)C(=O)C5CC5
  • InChIKey: FDLYAMZZIXQODN-UHFFFAOYSA-N
  • Mol. Mass: 434.4628
  • ALogP: 2.35
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

Australia

$11.8789 - $47.5158

United States

$85.7193 - $111.9298
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2h)-one | az2281 | azd221 | azd2281 | azd 2281 | azd-2281 | ku-0059436 | lymparza | lynparza | olaparib

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue